Affinage · Plasmodium

FabG

PF3D7_0922900 · 3-oxoacyl-[acyl-carrier-protein] reductase

Annotated
2026-09-08
19 papers in source corpus 9 papers cited in narrative 9 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

FabG (PF3D7_0922900) is the NADPH-dependent 3-oxoacyl-[acyl-carrier-protein] reductase that catalyzes the first reductive step of the iterative type II fatty acid biosynthesis (FAS-II) elongation cycle in Plasmodium falciparum (PMID:16225460, PMID:17485508). It is a homotetramer of the short-chain dehydrogenase/reductase (SDR) superfamily with a Ser/Tyr/Lys catalytic triad and a marked preference for NADPH over NADH (PMID:16225460, PMID:17654120). The enzyme operates by a steady-state ordered mechanism in which NADPH binds the free enzyme first; cofactor binding compacts the protein and increases affinity for the acetoacetyl-ACP substrate ~16-fold and for the acyl carrier protein PfACP ~3-fold, so that cofactor loading gates productive substrate engagement (PMID:16225460, PMID:16934037, PMID:17879351). Recognition of the physiological ACP-tethered substrate occurs through a positively charged, hydrophobic patch adjacent to the active site, with Arg187 and Arg230 mediating critical direct contacts to PfACP (PMID:16225460, PMID:18721141). Within a reconstituted FAS-II elongation module (FabB/F, FabG, FabZ, FabI), FabG acts sequentially in chain elongation, and its inhibition causes accumulation of the upstream intermediate, fixing its position in the pathway (PMID:17485508). FabG is inhibited in vitro by hexachlorophene and by flavonoids, most potently C-3 gallic acid esters of catechins (PMID:16225460, PMID:16722653). No genetic loss-of-function or in vivo parasite phenotype for FabG has been characterized in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2003 Medium

    Establishing that the P. falciparum FabG gene product is a bona fide, soluble, catalytically active reductase was the first step in defining a candidate FAS-II enzyme; recombinant expression answered whether the annotated gene encodes a functional 3-oxoacyl reductase.

    Evidence recombinant expression in E. coli with in vitro kinetics on acetoacetyl-CoA and homology modeling

    PMID:12646215

    Open questions at the time
    • kinetics measured on the CoA analog rather than the physiological ACP-linked substrate
    • no structural data to confirm the modeled NADPH specificity
    • cellular role in the parasite not addressed
  2. 2005 Low

    Refolding experiments probed the relationship between cofactor and enzyme integrity, showing NADPH is not merely catalytic but is required for correct folding of the recombinant enzyme.

    Evidence inclusion-body refolding restored only in the presence of NADPH and NaCl, with activity readout

    PMID:15939298

    Open questions at the time
    • cofactor-dependent folding is an indirect inference from a single refolding/activity assay
    • does not establish whether native in vivo folding requires NADPH
    • no structural characterization of the refolded species
  3. 2006 High

    The 1.5 Å crystal structure resolved the catalytic architecture and cofactor logic, answering how the enzyme is organized and why it prefers NADPH — defining the Ser/Tyr/Lys triad, the tetrameric assembly, and a steady-state ordered mechanism with NADPH binding first.

    Evidence X-ray crystallography with kinetic and product-inhibition analysis and inhibitor titration (hexachlorophene)

    PMID:16225460

    Open questions at the time
    • cofactor site occupied by sulphate rather than NADPH, so cofactor-bound conformation inferred
    • no co-crystal with ACP or acyl substrate
    • ACP recognition inferred from surface charge, not directly visualized
  4. 2006 Medium

    Binding studies established the allosteric consequence of the ordered mechanism — that NADPH loading actively primes the enzyme for substrate and ACP engagement — explaining how cofactor order translates into catalytic control.

    Evidence intrinsic and NADPH fluorescence, acrylamide quenching, and affinity measurements

    PMID:16934037

    Open questions at the time
    • negative cooperativity for NADPH not linked to a structural transition
    • physiological relevance of the observed reverse reaction unclear
    • single-lab fluorescence approach
  5. 2006 Medium

    Kinetic mode-of-inhibition analysis of flavonoids defined FabG as a druggable target and characterized how flavonoid inhibitors act, identifying noncompetitive inhibition and the most potent chemical class.

    Evidence in vitro enzyme inhibition kinetics and IC50 determination for catechin/flavonoid series

    PMID:16722653

    Open questions at the time
    • inhibition characterized only in vitro, not in parasites
    • binding site of noncompetitive inhibitors not mapped
    • selectivity over host reductases not established
  6. 2007 High

    In vitro reconstitution of the full FAS-II elongation module placed FabG in the sequential elongation cycle, answering where in the pathway the enzyme acts by showing its inhibition stalls the cycle at an upstream intermediate.

    Evidence reconstitution of FabB/F, FabG, FabZ, FabI with MALDI-TOF product profiling and inhibitor perturbation

    PMID:17485508

    Open questions at the time
    • pathway assembled in vitro rather than in the parasite
    • does not address regulation of the cycle in vivo
    • no genetic confirmation of FabG requirement
  7. 2007 Medium

    Biophysical characterization defined the enzyme's oligomeric state and stability, confirming a homotetrameric SDR-family protein with a two-state GdmCl unfolding transition.

    Evidence fluorescence, CD, denaturant unfolding, and thermodynamic analysis

    PMID:17654120

    Open questions at the time
    • stability measured on recombinant protein only
    • does not connect fold stability to catalytic regulation
    • single-lab thermodynamic model
  8. 2008 Medium

    Unfolding studies with cofactor revealed that NADPH binding compacts the enzyme and populates an activity-enhanced intermediate, linking cofactor binding to a defined conformational change.

    Evidence urea vs GdmCl unfolding with CD, fluorescence, cross-linking, SEC and acrylamide quenching

    PMID:17879351

    Open questions at the time
    • compaction inferred from indirect quenching/unfolding readouts
    • structural basis of the intermediate not resolved
    • physiological significance of the intermediate state unknown
  9. 2008 High

    Mutagenesis identified the specific residues mediating recognition of the physiological ACP-tethered substrate, answering how FabG discriminates ACP-linked acetoacetyl from the free CoA analog — Arg187 and Arg230 form the PfACP interaction site.

    Evidence site-directed mutagenesis with ACP-dependent vs ACP-independent activity, SPR, and fluorescence binding

    PMID:18721141

    Open questions at the time
    • ACP-bound complex not structurally resolved
    • mutant catalytic mechanism retained on CoA analog, so effect is on ACP docking only
    • no in vivo test of these residues

Open questions

Synthesis pass · forward-looking unresolved questions
  • The in vivo essentiality, genetic loss-of-function phenotype, and validation of FabG as an antimalarial drug target in the intact parasite remain unaddressed in the available corpus.
  • no gene knockout or conditional knockdown reported
  • no demonstration that inhibitors kill parasites via FabG
  • no structure of the FabG–PfACP or FabG–NADPH complex

Mechanism profile

Synthesis pass · controlled-vocabulary classification
Complex memberships
FAS-II elongation module (with FabB/F, FabZ, FabI; in vitro reconstitution)Homotetramer (FabG A4 assembly)

Evidence

Reading pass · 9 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2006 PfFabG (3-oxoacyl-ACP reductase) was crystallized at 1.5 Å resolution, revealing a homotetrameric structure with a catalytic triad of serine, tyrosine, and lysine aligned in an active conformation; a sulphate ion occupies the cofactor-binding site; and a cluster of positively charged residues at the active-site entrance is consistent with ACP substrate recognition. Kinetic and product inhibition studies indicated a steady-state ordered mechanism, with NADPH binding to the free enzyme first. Activity with NADH was <3% of that with NADPH. Hexachlorophene inhibited FabG with IC50 2.05 µM via non-linear competitive inhibition with respect to NADPH. X-ray crystallography (1.5 Å), fluorescence enhancement binding assays, kinetic analysis (steady-state ordered mechanism), product inhibition, in vitro enzymatic assay, inhibitor titration The Biochemical journal High 16225460
2003 Recombinant P. falciparum FabG expressed in E. coli is soluble and enzymatically active, catalyzing reduction of acetoacetyl-CoA with Km 75 µM, Vmax 0.0054 µmol/min/ml, and kcat 0.014 s−1. NADPH exhibits negative cooperativity in binding to FabG. Homology modeling using Brassica napus FabG as template provided a structural rationale for NADPH cofactor specificity. Recombinant protein expression in E. coli, in vitro enzymatic assay with acetoacetyl-CoA, kinetic characterization, homology modeling Biochemical and biophysical research communications Medium 12646215
2006 Binding of NADPH to PfFabG increases the binding affinity of substrate acetoacetyl-CoA by 16-fold and increases affinity for acyl carrier protein (ACP) approximately 3-fold, demonstrating ordered cofactor-mediated activation. PfFabG exhibits negative homotropic cooperativity for NADPH, which is enhanced in the presence of ACP. ACP increases NADPH accessibility to PfFabG. In the presence of NADP+, the reverse reaction is also observed (Ka = 23.17 µM−1). Intrinsic fluorescence spectroscopy (Trp334 nm), NADPH fluorescence (450 nm), acrylamide quenching assays, binding affinity measurements The FEBS journal Medium 16934037
2008 Arg187 and Arg230 of PfFabG are critical residues for interaction with P. falciparum ACP (PfACP). Mutagenesis of Arg187, Arg190, and Arg230 reduced affinities of PfFabG mutants for acetoacetyl-ACP (the physiological substrate) compared to wild-type, while activity with the substrate analog acetoacetyl-CoA was retained. Surface plasmon resonance and intrinsic fluorescence confirmed direct PfFabG–PfACP binding, identifying a positively charged/hydrophobic patch adjacent to the active site as the ACP interaction site. Site-directed mutagenesis, ACP-dependent and ACP-independent enzymatic assays, intrinsic fluorescence binding assays, surface plasmon resonance The FEBS journal High 18721141
2007 The elongation module of P. falciparum FAS-II was reconstituted in vitro using all four enzymes—FabB/F, FabG, FabZ, and FabI—and the reaction products were analyzed by MALDI-TOF MS. The distribution of acyl products from the reconstituted system matched the in vivo pattern, confirming FabG participates sequentially in iterative fatty acid chain elongation. Inhibition of FabG by (-)-catechin gallate led to accumulation of the upstream intermediate, detectable by MS. In vitro reconstitution of FAS-II elongation module, MALDI-TOF MS product analysis, inhibitor perturbation assay Antimicrobial agents and chemotherapy High 17485508
2007 PfFabG is a homotetramer (Mr ~120,000) belonging to the short-chain alcohol dehydrogenase/reductase (SDR) superfamily. Guanidinium chloride-induced denaturation follows a simple A4 ↔ 4A two-state unfolding model. Conformational stability (ΔGs) is 22.68 kcal/mol with ΔCp of 5.83 kcal/(mol·K), attributed to the large tetrameric size and buried hydrophobic core. Intrinsic fluorescence spectroscopy, circular dichroism, denaturant-induced unfolding, enzymatic activity measurements, thermodynamic analysis IUBMB life Medium 17654120
2008 Urea-induced unfolding of PfFabG is a multi-step process, whereas GdmCl-induced unfolding is two-state. In the presence of NADPH during urea unfolding, an activity-enhanced intermediate state is populated at ~1 M urea (90% activity recovered upon dilution), while NADPH provides no stabilization during GdmCl unfolding. NADPH binding leads to compaction of PfFabG structure as evidenced by decreased tryptophan accessibility to acrylamide quenching. Intrinsic fluorescence, circular dichroism, enzymatic activity measurement, glutaraldehyde cross-linking, size exclusion chromatography, acrylamide quenching Proteins Medium 17879351
2006 Flavonoids inhibit PfFabG in a noncompetitive manner (luteolin and (-)-catechin gallate used as model compounds in kinetic analysis), establishing the mode of inhibition at the enzyme level. C-3 gallic acid esters of catechins are the most potent inhibitors (IC50 0.2–1.1 µM). In vitro enzyme inhibition assay, kinetic analysis (mode of inhibition determination), IC50 determination Journal of medicinal chemistry Medium 16722653
2005 PfFabG overexpressed in E. coli as inclusion bodies could be correctly refolded only in the presence of the cofactor NADPH and 300 mM NaCl, demonstrating that NADPH is required for proper folding of the recombinant enzyme. The refolded protein was enzymatically active with acetoacetyl-CoA. Recombinant protein expression, inclusion body refolding, enzymatic activity assay Protein expression and purification Low 15939298

Source papers

Stage 0 corpus · 19 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2006 Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. Journal of medicinal chemistry 152 16722653
2010 Bromopyrrole alkaloids as lead compounds against protozoan parasites. Marine drugs 65 20714430
2006 Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis. The Biochemical journal 63 16225460
2003 Functional characterization of beta-ketoacyl-ACP reductase (FabG) from Plasmodium falciparum. Biochemical and biophysical research communications 38 12646215
2007 Anthecularin: a novel sesquiterpene lactone from Anthemis auriculata with antiprotozoal activity. The Journal of organic chemistry 29 17880246
2013 Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target. Journal of natural products 25 23806111
2008 Inhibiting enoyl-ACP reductase (FabI) across pathogenic microorganisms by linear sesquiterpene lactones from Anthemis auriculata. Phytomedicine : international journal of phytotherapy and phytopharmacology 24 18424102
2006 Analyses of co-operative transitions in Plasmodium falciparum beta-ketoacyl acyl carrier protein reductase upon co-factor and acyl carrier protein binding. The FEBS journal 24 16934037
2007 Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase. Antimicrobial agents and chemotherapy 21 17485508
2012 Marchantin A, a macrocyclic bisbibenzyl ether, isolated from the liverwort Marchantia polymorpha, inhibits protozoal growth in vitro. Phytomedicine : international journal of phytotherapy and phytopharmacology 17 22951393
2014 Compound prioritization from inverse docking experiment using receptor-centric and ligand-centric methods: a case study on Plasmodium falciparum Fab enzymes. Journal of molecular recognition : JMR 13 24591179
2013 Recent developments in the antiprotozoal and anticancer activities of the 2-alkynoic fatty acids. Chemistry and physics of lipids 10 23727443
2014 2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes. Bioorganic & medicinal chemistry letters 7 25103602
2008 A unique and differential effect of denaturants on cofactor mediated activation of Plasmodium falciparum beta-ketoacyl-ACP reductase. Proteins 5 17879351
2008 Deciphering the key residues in Plasmodium falciparum beta-ketoacyl acyl carrier protein reductase responsible for interactions with Plasmodium falciparum acyl carrier protein. The FEBS journal 5 18721141
2005 Production and purification of refolded recombinant Plasmodium falciparum beta-ketoacyl-ACP reductase from inclusion bodies. Protein expression and purification 4 15939298
2007 Conformational stability and thermodynamic characterization of homotetrameric Plasmodium falciparum beta-ketoacyl-ACP reductase. IUBMB life 3 17654120
2025 Computational Prioritization of T Cell Epitopes to Overcome HLA Restriction and Antigenic Diversity in Plasmodium falciparum. bioRxiv : the preprint server for biology 1 40791414
2026 TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes. Vaccine 0 41775037